[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021007970A - Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. - Google Patents

Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.

Info

Publication number
MX2021007970A
MX2021007970A MX2021007970A MX2021007970A MX2021007970A MX 2021007970 A MX2021007970 A MX 2021007970A MX 2021007970 A MX2021007970 A MX 2021007970A MX 2021007970 A MX2021007970 A MX 2021007970A MX 2021007970 A MX2021007970 A MX 2021007970A
Authority
MX
Mexico
Prior art keywords
preparation
oxo
method therefor
medical use
derivative
Prior art date
Application number
MX2021007970A
Other languages
English (en)
Inventor
Nan Yu
Feng He
Jiangtao Chi
Weikang Tao
Fanglong Yang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2021007970A publication Critical patent/MX2021007970A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describe un derivado de 6-oxo-1,6-dihidropiridaz ina, un método de preparación del mismo y su uso médico, en particular, un derivado de 6-oxo-1,6-dihidropiridazina representado por la fórmula general (I), un método de preparación del mismo y una composición farmacéutica que contiene el derivado, y su uso como un inhibidor de NaV y su uso en la preparación de un fármaco para el tratamiento y/o prevención del dolor y enfermedades relacionadas con el dolor. Cada sustituto en la fórmula general (I) es el mismo que se define en la descripción. (ver Fórmula).
MX2021007970A 2019-01-04 2020-01-03 Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. MX2021007970A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910006240 2019-01-04
CN201910380318 2019-05-08
CN201910384118 2019-05-09
CN201910567915 2019-06-27
PCT/CN2020/070186 WO2020140959A1 (zh) 2019-01-04 2020-01-03 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2021007970A true MX2021007970A (es) 2021-08-16

Family

ID=71406872

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007970A MX2021007970A (es) 2019-01-04 2020-01-03 Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.

Country Status (11)

Country Link
US (1) US20220073471A1 (es)
EP (1) EP3907218A4 (es)
JP (1) JP2022515909A (es)
KR (1) KR20210112336A (es)
CN (1) CN112955436B (es)
AU (1) AU2020205139A1 (es)
BR (1) BR112021012909A2 (es)
CA (1) CA3125244A1 (es)
MX (1) MX2021007970A (es)
TW (1) TW202039443A (es)
WO (1) WO2020140959A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202115038A (zh) * 2019-08-19 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用
TW202220962A (zh) * 2020-08-19 2022-06-01 大陸商江蘇恒瑞醫藥股份有限公司 選擇性NaV抑制劑的結晶形式及其製備方法
TW202214259A (zh) * 2020-08-19 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種選擇性ＮａＶ抑制劑的前藥及其晶型
TW202302118A (zh) * 2021-02-26 2023-01-16 大陸商江蘇恒瑞醫藥股份有限公司 一種選擇性ｎａｖ抑制劑的可藥用鹽、結晶形式及其製備方法
CN113277942B (zh) * 2021-05-25 2024-05-03 都创(上海)医药开发有限公司 一种基于微通道反应技术快速制备5-氯-2-氟-4-(三氟甲基)苯甲酸的方法
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
JP2024520649A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド （２ｒ，３ｓ，４ｓ，５ｒ）－４－［［３－（３，４－ジフルオロ－２－メトキシ－フェニル）－４，５－ジメチル－５－（トリフルオロメチル）テトラヒドロフラン－２－カルボニル］アミノ］ピリジン－２－カルボキサミドを含む固体剤形及び投与レジメン
CN117858875A (zh) 2021-06-04 2024-04-09 沃泰克斯药物股份有限公司 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂
EP4347584A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
EP4347583A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
JP2024529298A (ja) 2021-07-09 2024-08-06 プレキシウム インコーポレイテッド Ｉｋｚｆ２を調節するアリール化合物及び医薬組成物
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202408501A (zh) 2022-04-22 2024-03-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023256603A1 (en) 2022-04-22 2024-11-07 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023207949A1 (zh) * 2022-04-25 2023-11-02 中国科学院上海药物研究所 并环类化合物及其应用
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010003865A (es) * 2007-10-11 2010-06-01 Vertex Pharma Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
CN105026373B (zh) * 2013-01-31 2018-03-30 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
CA2898653C (en) * 2013-01-31 2021-09-28 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
MX2019013574A (es) * 2017-05-16 2019-12-18 Vertex Pharma Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio.

Also Published As

Publication number Publication date
CN112955436A (zh) 2021-06-11
JP2022515909A (ja) 2022-02-22
AU2020205139A1 (en) 2021-08-19
CA3125244A1 (en) 2020-07-09
US20220073471A1 (en) 2022-03-10
WO2020140959A1 (zh) 2020-07-09
EP3907218A4 (en) 2022-09-21
EP3907218A1 (en) 2021-11-10
TW202039443A (zh) 2020-11-01
CN112955436B (zh) 2023-08-11
KR20210112336A (ko) 2021-09-14
BR112021012909A2 (pt) 2021-09-14

Similar Documents

Publication Publication Date Title
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
CR20220363A (es) Compuestos tricíclicos sustituidos
MX2021004431A (es) Procesos novedosos.
MX2019013574A (es) Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio.
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
MX2022006865A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
JOP20190257A1 (ar) مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2020013785A (es) Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.
EP4342473A3 (en) Compounds useful in hiv therapy
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2019010695A (es) Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2 h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones.
MX2022000083A (es) Inhibidores de monoacilglicerol lipasa (magl) heterociclicos.
EP4282414A3 (en) Modified release tablet formulations containing phosphodiesterase inhibitors
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2021013576A (es) Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.
EP4410295A3 (en) Use of vibegron to treat overactive bladder